Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Christina U Lorentz, PhD, Norah G Verbout, PhD, Joseph J Shatzel, MD, Michael Wallisch, PhD, Brandon D Markway, PhD, Monica T Hinds, PhD, Owen J T McCarty, PhD, David Gailani, MD, Jeffrey I. Weitz, MDFRCPC, Erik I Tucker, PhD, András Gruber, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139948

Published: 2020

Journal Articles

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Norah G Verbout, PhD, Christina U Lorentz, PhD, Brandon D Markway, PhD, Joseph J Shatzel, MD, Erik I Tucker, PhD, Andras Gruber, MD

Blood (2019) 134 (Supplement_1): 2433.

https://doi.org/10.1182/blood-2019-124999

Published: 2019

Journal Articles

Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion

Christina U Lorentz, PhD, Norah G Verbout, PhD, Zhiping Cao, Helen Liu, Owen J.T. McCarty, PhD, Erik I. Tucker, PhD, Andras Gruber, MD, Donna Van Winkle, PhD

Blood (2014) 124 (21): 2873.

https://doi.org/10.1182/blood.V124.21.2873.2873

Published: 2014

Journal Articles

Rapid Interruption Of Occlusive Thrombus Formation By The Protein C Activator Enzyme EWE Thrombin (ProCase) In Primates

Erik I Tucker, PhD, Michael Wallisch, PhD, Philberta Y Leung, PhD, Andras Gruber, MD, Enrico Di Cera, MD, Norah G Verbout, PhD

Blood (2013) 122 (21): 202.

https://doi.org/10.1182/blood.V122.21.202.202

Published: 2013

Journal Articles

Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates

Erik I. Tucker, PhD, Ulla M Marzec, MS, Philberta Y Leung, PhD, Stephen R Hanson, PhD, Prof., Norah G Verbout, PhD, Sawan Hurst, MS, Owen J.T. McCarty, PhD, David Gailani, MD, Andras Gruber, MD

Blood (2011) 118 (21): 1173.

https://doi.org/10.1182/blood.V118.21.1173.1173

Published: 2011

NARROW

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion

Rapid Interruption Of Occlusive Thrombus Formation By The Protein C Activator Enzyme EWE Thrombin (ProCase) In Primates

Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Inhibition of Factor XIIa-Mediated Factor XI Activation Reduces Infarct Size in a Mouse Model of Myocardial Ischemia and Reperfusion

Rapid Interruption Of Occlusive Thrombus Formation By The Protein C Activator Enzyme EWE Thrombin (ProCase) In Primates

Apple Domain-Specific Anti-Factor XI Antibodies Inhibit Venous-Type Thrombosis with Improved Hemostatic Safety Profiles Compared to Enoxaparin in Primates

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only